IL-17A (Interleukin-17A): Complete Research Profile — The Th17-Derived Cytokine Driving Autoimmune Inflammation via IL-17RA/ACT1/NF-κB Signaling, Psoriasis, Spondyloarthritis, and the Basis for Anti-IL-17 Biologics (2026)

What Is IL-17A?

Interleukin-17A (IL-17A) is the founding and most extensively studied member of the IL-17 cytokine family, a group of six structurally related proteins (IL-17A through IL-17F) that coordinate innate and adaptive inflammatory responses. Encoded by the IL17A gene on chromosome 6p12, IL-17A is a disulfide-linked homodimeric glycoprotein that acts as a master orchestrator of neutrophil-dominant inflammation, mucosal barrier defense, and — when dysregulated — the destructive autoimmune tissue damage characteristic of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

IL-17A is primarily produced by CD4⁺ Th17 helper T cells, but also by CD8⁺ Tc17 cells, γδ T cells, natural killer cells, innate lymphoid group 3 (ILC3) cells, mast cells, and activated neutrophils themselves. Its principal receptor complex — the IL-17RA/IL-17RC heterodimer — is expressed on structural cells (keratinocytes, fibroblasts, chondrocytes, epithelial cells) and myeloid cells, making IL-17A a central node through which adaptive immune signals are translated into tissue-level inflammatory programs.

Understanding IL-17A biology has transformed the management of inflammatory skin and joint disease. Four approved anti-IL-17 biologics (secukinumab, ixekizumab, bimekizumab, and brodalumab) now represent some of the most effective research tools for dissecting IL-17A–dependent pathology, and the expanding IL-17 inhibitor class continues to illuminate the mechanistic role of this cytokine across an ever-wider array of inflammatory conditions.

> Research Use Only. All content on this page describes IL-17A in the context of basic science and preclinical laboratory research. This information is not intended as guidance for human or animal use, therapeutic application, or clinical practice.

---

Gene Structure, Protein Architecture, and Isoforms

The *IL17A* Gene and Encoded Protein

The human IL17A gene spans approximately 4.3 kb on chromosome 6p12 and encodes a 155-amino acid precursor protein with a 23-residue signal peptide, yielding a 132-amino acid mature form (approximately 17 kDa per monomer; ~35 kDa homodimer). The mature protein is N-glycosylated, with glycosylation contributing to secretory stability and receptor-binding kinetics.

IL-17A shares a conserved cystine-knot fold — a structural motif present across the IL-17 family — defined by four conserved cysteine residues forming two intrachain disulfide bonds. Unlike classical growth factors with complete cystine knots, IL-17 family proteins lack the third disulfide, creating what is described as an "incomplete" or "open" cystine-knot topology that permits both homodimerization and heterodimerization.

Homodimer and Heterodimer Forms

IL-17A circulates and signals principally as a disulfide-linked homodimer (IL-17A/A), but can also form a heterodimer with IL-17F (IL-17A/F). The IL-17A/F heterodimer is biologically active and engages the same IL-17RA/IL-17RC receptor complex as the homodimer, though with distinct potency profiles depending on cellular context. Structural analyses have revealed that the heterodimer adopts a "two-faced" architecture in which IL-17RA can engage either the A-face or the F-face with comparable affinity, distinguishing it mechanistically from the homodimeric forms.

The relative abundance of IL-17A/A vs. IL-17A/F in different disease compartments may influence the dominant downstream signaling profile, a distinction increasingly relevant to differential sensitivity of anti-IL-17A antibodies (which neutralize only IL-17A-containing forms) vs. anti-IL-17RA antibodies (which block signaling from all IL-17 family members through IL-17RA).

---

Cellular Sources and Regulation of IL-17A Production

Th17 Cell Differentiation

The canonical source of IL-17A is the Th17 cell lineage, a CD4⁺ T helper subset whose differentiation from naïve CD4⁺ precursors is driven by the transcription factors RORγt (the master regulator) and STAT3, downstream of a cytokine milieu dominated by TGF-β + IL-6 (initial Th17 priming), IL-21 (autocrine amplification), and IL-23 (stabilization and expansion of the mature, pathogenic Th17 phenotype).

The IL-23/Th17 axis is central to the inflammatory loop in autoimmune conditions: IL-23 (produced by dendritic cells and macrophages) maintains and expands Th17 populations that in turn secrete IL-17A, which then drives tissue inflammation that further activates innate immune cells to produce more IL-23. This feed-forward circuit is exploited therapeutically by the IL-17 and IL-23 inhibitor classes, which interrupt the loop at different points.

Non-Th17 Sources

Research has identified numerous IL-17A-producing cell populations beyond classical Th17 cells:

• •CD8⁺ Tc17 cells: relevant in tumor microenvironments and viral immunity
• •γδ T cells: major early IL-17A source in skin and mucosal barriers, responding rapidly to stress signals
• •Group 3 Innate Lymphoid Cells (ILC3): important in gut homeostasis and mucosal defense
• •Mast cells: contribute to IL-17A production in allergic and barrier tissue contexts
• •Neutrophils: can produce IL-17A themselves in an autocrine amplification loop, particularly in vertebral biopsies from ankylosing spondylitis patients where IL-17⁺ neutrophils are the predominant IL-17-expressing population

---

IL-17A Receptor Biology: The IL-17RA/IL-17RC Heterodimer

Receptor Subunits

IL-17A signals through a cell-surface receptor complex composed of two type I transmembrane proteins:

• •IL-17RA (CD217): the larger, primary binding subunit; broadly expressed on structural and hematopoietic cells; contains an extracellular fibronectin III-like domain and an intracellular SEFIR (Similar Expression to FGF genes and IL-17Rs) domain essential for signal transduction
• •IL-17RC: the co-receptor subunit; expression more restricted to stromal and epithelial cells; required for high-affinity ligand binding

Together, IL-17RA and IL-17RC form a heterodimeric complex with nanomolar affinity for IL-17A/A. An IL-17RC homodimer has also been reported as an alternative IL-17A receptor complex capable of IL-17RA-independent signaling, though its physiological significance remains under investigation.

Receptor expression pattern: IL-17RA is broadly expressed, making IL-17A one of the few cytokines capable of signaling in virtually every tissue. IL-17RC expression on keratinocytes, fibroblasts, synoviocytes, and chondrocytes is particularly relevant to its roles in skin and joint disease. Endothelial cells and smooth muscle cells also respond to IL-17A, contributing to vascular effects.

---

Downstream Signaling: ACT1, TRAFs, NF-κB, and Beyond

The ACT1–TRAF6–NF-κB Core Pathway

Upon IL-17A binding to the IL-17RA/IL-17RC complex, the adapter protein ACT1 (Nuclear Factor NF-κB Activator 1, also called CIKS) is recruited to the intracellular SEFIR domain of IL-17RA via homotypic SEFIR–SEFIR interaction. ACT1, which functions as an E3 ubiquitin ligase, then catalyzes the K63-linked polyubiquitination of TRAF6.

TRAF6, upon ubiquitination, recruits and activates TAK1 (TGF-β–activated kinase 1), which in turn phosphorylates the IKK complex (IKKα/IKKβ/NEMO). IKK activation leads to phosphorylation and proteasomal degradation of IκB, releasing NF-κB (predominantly p65/p50 heterodimers) to translocate to the nucleus and drive transcription of a broad proinflammatory gene program:

• •Cytokines and chemokines: IL-6, IL-8 (CXCL8), CXCL1, CXCL5, CCL2, G-CSF — collectively driving neutrophil recruitment and amplification of innate inflammation
• •Antimicrobial peptides (AMPs): β-defensins, S100A7 (psoriasin), S100A8/A9 (calprotectin) — relevant to epidermal barrier function and antimicrobial defense
• •Matrix metalloproteinases (MMPs): MMP-1, MMP-3, MMP-13 — driving tissue remodeling and joint destruction
• •Acute-phase reactants: fibrinogen, serum amyloid A

MAPK Signaling Branch

Parallel to NF-κB activation, ACT1–TRAF6 signaling also engages MAPK pathways (p38, ERK1/2, JNK). The p38 MAPK pathway, in particular, regulates post-transcriptional stability of IL-17A target gene mRNAs by phosphorylating RNA-binding proteins (including HuR/ELAVL1) that stabilize AU-rich element (ARE)-containing transcripts. This post-transcriptional amplification layer means that even modest IL-17A signals can produce sustained, amplified inflammatory gene expression.

The TRAF2/TRAF5 mRNA Stability Branch

ACT1 also recruits a second TRAF complex — the ACT1–TRAF2–TRAF5 module — which acts separately from the NF-κB/MAPK pathway to control mRNA stability of IL-17 target genes. This branch stabilizes pro-inflammatory transcripts (including CXCL1, CXCL5, MMP3) by sequestering mRNA destabilizing factors. Genetic studies have established that disruption of this branch specifically affects chemokine production without globally ablating NF-κB signaling, providing mechanistic separation between IL-17A's roles in neutrophil recruitment vs. broader inflammatory amplification.

C/EBP Transcription Factor Engagement

Both C/EBPβ and C/EBPδ are activated downstream of IL-17A signaling, cooperating with NF-κB to drive maximal transcription of proinflammatory genes. C/EBP factors also regulate IL-17A target genes in a cell-type-specific manner, contributing to differential responses in keratinocytes vs. synoviocytes vs. hepatocytes.

Synergy with TNF-α and IL-1β

A critical feature of IL-17A biology is its potent synergy with TNF-α and IL-1β. When these cytokines co-stimulate target cells, the combined output of proinflammatory mediators far exceeds the additive sum of individual stimulations. This synergy operates at both the transcriptional level (co-activation of NF-κB by independent upstream signals) and the post-transcriptional level (cooperative mRNA stabilization). The TNF/IL-17A synergy is mechanistically central to psoriatic disease, where both pathways are simultaneously active.

---

Biological Functions of IL-17A

Neutrophil Recruitment and Antimicrobial Defense

The primary physiological role of IL-17A is the orchestration of neutrophil-dominant host defense at epithelial barriers (skin, lung, gut, oral mucosa). Through the induction of CXCL1, CXCL5, CXCL8 (IL-8), and G-CSF from structural cells, IL-17A creates a chemokine gradient and colony-stimulating support that recruits, activates, and locally expands neutrophil populations. This function is phylogenetically ancient and broadly conserved, explaining why IL-17A-deficient mice are highly susceptible to extracellular bacterial and fungal pathogens (particularly Candida albicans, Staphylococcus aureus, and Klebsiella pneumoniae).

Consistent with this function, patients receiving IL-17A–targeting biologics show modestly increased rates of mucocutaneous candidiasis (primarily oropharyngeal), reflecting a physiologically significant (though usually manageable) reduction in antifungal mucosal surveillance.

Barrier Integrity and Epithelial Remodeling

Beyond immune cell recruitment, IL-17A directly modulates epithelial biology. In skin, IL-17A stimulates keratinocyte proliferation and differentiation, contributing to the acanthosis (epidermal thickening) and disrupted differentiation program characteristic of psoriatic plaques. IL-17A also induces keratinocyte production of antimicrobial peptides (β-defensins 2/3, S100A7, S100A8/A9), which serve dual roles in antimicrobial defense and — paradoxically — as damage-associated molecular patterns (DAMPs) that further amplify innate immune activation in the inflammatory context.

In the intestinal epithelium, IL-17A supports tight junction integrity and mucosal barrier function at physiological concentrations. However, chronic IL-17A exposure in inflammatory bowel disease can paradoxically disrupt barrier function through MMP-mediated degradation of extracellular matrix and tight junction proteins.

Bone Metabolism and Joint Remodeling

In articular biology, IL-17A promotes osteoclastogenesis by stimulating synoviocytes and osteoblasts to express RANKL, the critical signal for osteoclast differentiation and activation. IL-17A also directly induces MMP production from synoviocytes and chondrocytes, driving cartilage degradation. These mechanisms underlie the joint erosion and new bone formation that characterize psoriatic arthritis and ankylosing spondylitis — and explain why IL-17A inhibition is effective not only for skin clearance but for protecting structural joint integrity.

---

IL-17A in Disease Pathology

Psoriasis

Psoriasis represents the paradigmatic IL-17A–driven disease. In plaque psoriasis, Th17 cells and ILC3s in the dermis produce IL-17A, which acts on keratinocytes to drive:

• •Epidermal hyperproliferation (acanthosis)
• •Impaired terminal differentiation (incomplete cornification)
• •Neutrophil recruitment forming characteristic Munro's microabscesses
• •Upregulation of AMPs that serve as autoantigens and innate immune amplifiers

The centrality of the IL-17A axis is confirmed by the extraordinary efficacy of IL-17A inhibitors in clinical psoriasis research — PASI 90 response rates of 70–80% with secukinumab and ixekizumab, reaching >85% with bimekizumab (which also blocks IL-17F), substantially exceeding earlier biologics targeting TNF-α or IL-12/23.

Psoriatic Arthritis and Ankylosing Spondylitis

In spondyloarthritis spectrum diseases, the HLA-B27/IL-17A axis is mechanistically central. HLA-B27 homodimers activate an unfolded protein response that upregulates IL-23 production from macrophages, which then drives Th17 expansion and IL-17A secretion. Notably, in ankylosing spondylitis, IL-17⁺ neutrophils (rather than T cells) appear to be the dominant IL-17A source in the vertebral lesions that characterize this disease, suggesting tissue-compartment-specific cellular sources. Secukinumab was the first biologic approved for both radiographic and non-radiographic axial spondyloarthritis, directly establishing IL-17A as a tractable research and therapeutic target in this condition.

Inflammatory Bowel Disease

In Crohn's disease and ulcerative colitis, the role of IL-17A is more complex. While gut-resident Th17 cells and ILC3s produce IL-17A and contribute to mucosal inflammation, clinical data with anti-IL-17A antibodies in IBD have been disappointing or even harmful, suggesting that protective mucosal barrier roles of IL-17A may outweigh its pathological contributions in this specific tissue context. This stands in instructive contrast to skin and joint disease, and illustrates the tissue-context dependence of IL-17A function — a critical consideration for research models.

Rheumatoid Arthritis

Th17 cells and synovial fibroblast-derived IL-17A contribute to joint inflammation in RA, though the disease is primarily driven by TNF-α and IL-6. IL-17A inhibition has shown modest efficacy in RA research models, with the combination of IL-17A blockade and TNF inhibition showing additive effects — consistent with the mechanistic synergy between these pathways.

Neuroinflammation

Emerging research has documented IL-17A/IL-17RA signaling in the CNS context, including activation of the IL-17A/TRAF6/NF-κB pathway in models of Alzheimer's disease pathology (Aβ-induced neurotoxicity) and in multiple sclerosis. Brain-infiltrating Th17 cells and γδ T cells are established contributors to neuroinflammatory pathology, and IL-17RA expression on neurons, astrocytes, and microglia provides the cellular substrate for direct cytokine effects in neural tissue.

---

Anti-IL-17 Research Tools: Biologics and Their Mechanistic Distinctions

Four FDA-approved anti-IL-17 biologics now serve as essential research tools for dissecting IL-17A–dependent biology:

The mechanistic distinction between these agents is scientifically important:

• •Secukinumab and ixekizumab block only IL-17A-containing forms (IL-17A/A and IL-17A/F), leaving IL-17F/F signaling intact
• •Bimekizumab adds IL-17F/F neutralization, which research data suggest enhances barrier function suppression and speeds epidermal clearance
• •Brodalumab blocks all IL-17RA-mediated signaling, making it the most complete research tool for total IL-17 pathway ablation

Comparative drug survival and efficacy studies (PMID 37926830) confirm that while IL-17 inhibitors achieve faster PASI 90/PASI 100 responses than IL-23 inhibitors in psoriasis research (median weeks to PASI100: bimekizumab 5.5 wk, brodalumab 7 wk, ixekizumab 8.5 wk, secukinumab 15 wk), long-term drug survival at 24 months favors IL-23 inhibitors, suggesting different kinetics of pathway dependency in chronic disease maintenance.

---

Research Applications and In Vitro Models

Recombinant IL-17A for Cell Stimulation

Recombinant human IL-17A (typically 10–100 ng/mL) is widely used to stimulate:

• •Primary keratinocytes for psoriasis-relevant gene expression panels (β-defensin 2/3, CXCL8, S100A7, S100A8)
• •Synoviocytes and chondrocytes for joint inflammation models (MMP-1, MMP-3, RANKL induction)
• •Airway epithelial cells for mucosal inflammation models
• •Intestinal organoids for gut barrier integrity studies

Importantly, IL-17A stimulation in monoculture often produces relatively modest responses compared to TNF-α + IL-17A co-stimulation, which reflects the in vivo co-production of these cytokines in disease tissue. Well-designed IL-17A research should include co-stimulation conditions.

Reporter Systems and Pathway Readouts

Key readouts for IL-17A signaling in research settings:

• •NF-κB luciferase reporter assays: sensitive measure of canonical IL-17A/ACT1/TRAF6/IKK/NF-κB activation
• •CXCL1/CXCL8 ELISA: functional readout of IL-17A bioactivity in stromal cell conditioned medium
• •Phospho-p65, phospho-IκB Western blot: direct NF-κB pathway activation markers
• •Phospho-p38/ERK: MAPK arm activation
• •ACT1 co-immunoprecipitation with IL-17RA: measures receptor–adaptor engagement

Genetic Research Tools

• •IL17A knockout mice: well-characterized models showing susceptibility to mucosal pathogens but protection from autoimmune inflammation models
• •RORγt-deficient mice: defective Th17 differentiation with near-complete IL-17A deficiency
• •IL-17A fate-mapping reporters (IL-17A-Cre/Rosa26-reporter): lineage tracing of IL-17A-producing cells across disease progression
• •Human GWAS hits: IL17A region SNPs associated with psoriasis susceptibility; IL17RA splice variants associated with altered signaling kinetics

---

IL-17A Measurement and Biomarker Research

Circulating IL-17A Measurement

Measuring circulating IL-17A by standard ELISA is technically challenging due to its relatively low serum concentrations (~1–50 pg/mL in healthy individuals) and short half-life. More sensitive Simoa (single-molecule array) or electrochemiluminescence platforms (MSD) are preferred for clinical research applications. Tissue-level IL-17A measurement (immunohistochemistry, RNAScope, single-cell RNA-seq) provides more robust mechanistic data in disease models.

Single-Cell Analyses

Single-cell RNA sequencing of psoriatic skin, ankylosing spondylitis vertebral lesions, and synovial tissue from PsA has provided unprecedented resolution of IL-17A source cell populations. These data have confirmed the heterogeneity of "Th17-like" IL-17A producers (classical Th17, non-classical IL-10-co-producing Th17, ex-Th17 cells) and identified γδ T cells and ILC3s as quantitatively significant IL-17A contributors in certain tissue compartments.

---

Current Research Frontiers

IL-17A in Cancer Biology

IL-17A has complex, context-dependent roles in cancer. In colorectal cancer, IL-17A-producing tumor-infiltrating T cells have been associated with poor prognosis, promoting tumor growth through NF-κB-driven angiogenesis and immune evasion. Conversely, in certain viral-driven cancers, IL-17A contributes to immunosurveillance through neutrophil-mediated tumor killing. A 2024 systematic review identified IL-17A pathway activity as a significant modulator of tumor microenvironment composition across multiple cancer types (PMC11519...Frontiers Immunol 2024), making it an active research target in immuno-oncology.

Peptide Therapeutics Targeting IL-17RA

Beyond full monoclonal antibodies, research into synthetic peptide inhibitors of the IL-17A/IL-17RA interface is active. A 2025 study (PMC11929782) described innovative peptide therapeutics targeting IL-17RA to regulate inflammatory responses, leveraging structural data on the IL-17RA binding epitope to design constrained peptides with improved selectivity profiles compared to small molecules. These represent early-stage research tools with potential advantages in tissue penetration and manufacturing compared to full antibody biologics.

The ACT1 E3 Ligase as a Drug Target

Because ACT1 sits at the apex of the IL-17A–specific signaling cascade (before bifurcation into TRAF6/NF-κB and TRAF2/5/mRNA stability branches), small-molecule inhibitors of ACT1's E3 ubiquitin ligase activity represent an attractive strategy for selectively inhibiting IL-17A downstream effects without globally suppressing other cytokine pathways. Research tools targeting the ACT1–TRAF6 interaction surface are in early investigation.

IL-17A in Metabolic Disease

Emerging data link IL-17A to adipose tissue inflammation, insulin resistance, and non-alcoholic steatohepatitis (NASH). IL-17RA expression on hepatocytes and hepatic stellate cells, combined with Th17 infiltration in obese adipose tissue, suggests that IL-17A may contribute to metabolic-inflammatory crosstalk beyond classical autoimmune contexts. This represents a growing research area for IL-17A biology.

---

Summary

IL-17A is a disulfide-linked homodimeric cytokine produced predominantly by Th17 cells and a diverse array of innate immune effectors. Its signaling through the IL-17RA/IL-17RC heterodimer, mediated by the ACT1–TRAF6–NF-κB and ACT1–TRAF2/5–mRNA stability axes, drives neutrophil recruitment, antimicrobial peptide production, and tissue remodeling programs that are essential for host defense but pathological when chronically activated.

The IL-17A axis is causally implicated in psoriasis, psoriatic arthritis, ankylosing spondylitis, and multiple other inflammatory conditions, a conclusion validated by the outstanding efficacy of four approved anti-IL-17 biologics (secukinumab, ixekizumab, bimekizumab, and brodalumab). Understanding the mechanistic distinctions between IL-17A/A homodimer, IL-17A/F heterodimer, and pan-IL-17RA signaling — and how these map to specific disease presentations and treatment responses — remains an active frontier in cytokine biology research.

---

Key References

1. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600. PMID 25145755

2. Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016;22(3):230-241. PMID 26837266

3. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149-162. PMID 21349428

5. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol. 2007;179(6):4135-4141. PMID 17785852

6. Mastorino L, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis. JDDG. 2024;22(1):45-55. PMID 37926830

7. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1-2):419-429. PMID 21964750

8. Brusbardis V, et al. TRAF Regulation of IL-17 Cytokine Signaling. Front Immunol. 2019;10:1293. PMC6610456

10. Innovative peptide therapeutics targeting IL17RA to regulate inflammatory responses. PMC11929782. PMC11929782